Hwail Pharmaceutical Co.Ltd (061250) — Capital Reinvestment Ratio
Hwail Pharmaceutical Co.Ltd (061250) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩6.82 Billion) in capital expenditures (₩1.39 Billion). See net asset quality index of Hwail Pharmaceutical Co.Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hwail Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2011–2024)
This chart tracks Hwail Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 10 annual periods. Check 061250 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd from 2011 to 2024. For live market cap and broader valuation context, see market cap of Hwail Pharmaceutical Co.Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.98x | ₩11.63 Billion | ₩34.63 Billion | ▲ +894.9% |
| 2023 | 0.30x | ₩7.02 Billion | ₩2.10 Billion | ▲ +143.3% |
| 2021 | 0.12x | ₩20.09 Billion | ₩2.47 Billion | ▼ -58.2% |
| 2019 | 0.29x | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩8.34 Billion | ₩513.62 Million | ▲ +42.9% |
| 2016 | 0.04x | ₩9.58 Billion | ₩413.00 Million | ▼ -96.7% |
| 2013 | 1.32x | ₩6.97 Billion | ₩9.18 Billion | ▼ -82.9% |
| 2012 | 7.69x | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩7.86 Billion | ₩5.32 Billion | — |